Related Experiment Video
Updated: Jun 24, 2025
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
CAR-T therapy for ovarian cancer: Recent advances and future directions
Qianling Xin1, Yizhao Chen2, Xiaojing Sun1
1Anhui Women and Children's Medical Center, Hefei Maternal and Child Health Hospital, Hefei, China.
Abstract:
Ovarian cancer (OC) is a common gynecological tumor with high mortality, which is difficult to control its progression with conventional treatments and is prone to recurrence. Recent studies have identified OC as an immunogenic tumor that can be recognized by the host immune system. Immunotherapy for OC is being evaluated, but approaches such as immune checkpoint inhibitors have limited efficacy, adoptive cell therapy is an alternative therapy, in which CAR(chimeric antigen receptor)-T therapy has been applied to the clinical treatment of hematological malignancies. In addition, CAR-NK and CAR-macrophage (CAR-M) have also shown great potential in the treatment of solid tumors. Here, we discuss recent advances in preclinical and clinical studies of CAR-T for OC treatment, introduce the efforts made by researchers to modify the structure of CAR in order to achieve effective OC immunotherapy, as well as the research status of CAR-NK and CAR-M, and highlight emerging therapeutic opportunities that can be utilized to improve the survival of patients with OC using CAR-based adoptive cell therapy.
Insights
Chimeric antigen receptor (CAR)-based adoptive cell therapies, including CAR-T, CAR-NK, and CAR-macrophage (CAR-M) cells, show promise for treating ovarian cancer (OC). These advanced immunotherapies offer new hope for improving patient survival in this challenging gynecological tumor.
Area of Science:
- Oncology
- Immunology
- Cell Therapy
Background:
- Ovarian cancer (OC) presents a significant challenge due to high mortality, treatment resistance, and recurrence.
- OC is recognized as an immunogenic tumor, making it a target for immunotherapy.
- Current immunotherapies like immune checkpoint inhibitors show limited efficacy in OC.
Purpose of the Study:
- To review recent advances in CAR-T, CAR-NK, and CAR-macrophage (CAR-M) cell therapies for ovarian cancer.
- To discuss structural modifications of CARs aimed at enhancing OC immunotherapy effectiveness.
- To highlight emerging therapeutic opportunities in CAR-based adoptive cell therapy for improving OC patient survival.
Main Methods:
- Review of preclinical and clinical studies on CAR-T therapy for OC.
- Analysis of research on CAR-NK and CAR-M cell potential in solid tumors, including OC.
- Discussion of CAR structural modifications for improved efficacy.
Main Results:
- CAR-T therapy, initially successful in hematological malignancies, is being explored for OC.
- CAR-NK and CAR-M therapies demonstrate significant potential for treating solid tumors like OC.
- Ongoing research focuses on optimizing CAR structures for better OC targeting and immune response.
Conclusions:
- CAR-based adoptive cell therapies represent a promising frontier for ovarian cancer treatment.
- Further research and development in CAR engineering are crucial for overcoming current limitations.
- These advanced immunotherapies hold potential to significantly improve outcomes for ovarian cancer patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...